文献速递甲状腺核医学核素与放射性配体治疗

分化型甲状腺癌中高危患者放射性碘治疗后成功消融率的系统评价与荟萃分析

Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-06-18

该系统评价与荟萃分析纳入9项研究共3103例中高危复发风险的分化型甲状腺癌患者,评估放射性碘治疗后成功消融率。汇总成功消融率为71%,中危组72%高于高危组52%;中危患者成功消融后6.4年随访汇总复发率仅2%,未成功消融者为14%。

要点

  • 中高危DTC患者RAI治疗后汇总成功消融率为71%,中危72%高于高危52%。
  • 中危患者成功消融后6.4年汇总复发率2%,未成功消融者为14%。
  • 较高 administered RAI 活度与全人群及高危亚组较低成功消融率相关。

核心结论

  • 3103例中高危持续/复发疾病风险患者中71%达到成功消融。
  • 中危患者成功消融后后续复发概率低,多数复发见于首次控制时已有异常发现者。

研究设计与样本

  • 按PRISMA声明检索PubMed、Scopus和Web of Science数据库的系统评价与荟萃分析。
  • 最终分析纳入9项研究共3103例中高危复发风险的分化型甲状腺癌患者。

主要发现

  • 成功消融率范围为51%至94%,汇总成功消融率为71%。
  • 中危组成功消融率72%高于高危组52%。
  • 评估的研究间存在显著异质性。
  • 较高 administered RAI 活度与全人群及高危亚组较低成功消融率相关。
  • 中危患者成功消融后6.4年随访汇总复发率为2%,未成功消融者为14%。

关键数值与推荐

  • 中高危复发风险DTC患者RAI治疗后汇总成功消融率为71%。
  • 中危患者汇总成功消融率72%,高危患者52%。
  • 中危患者成功消融后6.4年汇总复发率2%,未成功消融者14%。

临床怎么用

  • 中危DTC患者RAI治疗后成功消融概率较高且后续复发风险低。
  • 首次控制时已有异常发现者需关注后续复发。

局限性

  • 评估的研究间存在显著异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We performed a systematic review and a meta-analysis to investigate the successful ablation rate after radioiodine (RAI) administration in patients with differentiated thyroid cancer (DTC) at intermediate-high risk of recurrence. METHODS: A comprehensive literature search of the PubMed, Scopus, and Web of Science databases was conducted according to the PRISMA statement. RESULTS: The final analysis included 9 studies accounting for 3103 patients at intermediate-high risk of recurrence. In these patients, the successful ablation rates ranged from 51 to 94% with a 71% pooled successful ablation and were higher in intermediate (72%) than in high (52%)-risk patients. Despite the rigorous inclusion standards, a significant heterogeneity among the evaluated studies was observed. Higher administered RAI activities are associated with a lower successful ablation rate in the whole population and in the subgroup of high-risk patients. Furthermore, pooled recurrence rate in intermediate-risk patients achieving successful ablation was only 2% during the subsequent 6.4-year follow-up while the pooled recurrence rate was 14% in patients who did not achieve a successful ablation. CONCLUSION: In a large sample of 3103 patients at intermediate-high risk of persistent/recurrent disease, 71% of patients achieved a successful ablation. In these intermediate-risk patients, the probability of subsequent recurrence is low and most recurrence occurred in those with already abnormal findings at the first control.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Klain M, Nappi C, Zampella E, et al. Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis. Eur J Nucl Med Mol Imaging. 2021. PMID: 34142215. doi:10.1007/s00259-021-05440-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。